COVID-19 neutralizing antibody in phase-1 clinical trial in Shanghai

A recombinant, fully human, monoclonal neutralizing antibody against COVID-19 entered the phase-1 clinical trial as it was injected into the first subject on Sunday in Shanghai. The clinical trial of the antibody was approved by the National Medical Products Administration on Friday.